ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,146.86
-0.21%
Dow Jones
38,589.16
-0.15%
Gold vs US Dollar
2,333.015
0.00%
Brent Oil
82.275
0.00%
Bitcoin
66,518.62
0.49%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Geron Corp (GERN)

  7. Geron Corp (GERN) News

Geron (GERN)

Geron Corp
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:GERN
DateTimeSourceHeadlineSymbolCompany
12/06/202421:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GERNGeron Corp
12/06/202421:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GERNGeron Corp
10/06/202422:53Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GERNGeron Corp
10/06/202417:30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GERNGeron Corp
07/06/202421:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GERNGeron Corp
07/06/202421:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GERNGeron Corp
07/06/202421:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GERNGeron Corp
07/06/202421:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GERNGeron Corp
07/06/202421:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GERNGeron Corp
07/06/202421:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GERNGeron Corp
07/06/202421:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GERNGeron Corp
07/06/202402:58Business WireGeron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent AnemiaNASDAQ:GERNGeron Corp
05/06/202421:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GERNGeron Corp
04/06/202422:02Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GERNGeron Corp
17/05/202421:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GERNGeron Corp
16/05/202421:30Business WireGeron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:GERNGeron Corp
15/05/202421:07Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GERNGeron Corp
13/05/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GERNGeron Corp
02/05/202412:00Business WireGeron Corporation Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:GERNGeron Corp
25/04/202421:30Business WireGeron to Announce First Quarter 2024 Financial Results on May 2, 2024NASDAQ:GERNGeron Corp
18/04/202421:30Business WireGeron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:GERNGeron Corp
03/04/202421:30Business WireGeron to Participate at Upcoming Investor Conferences in AprilNASDAQ:GERNGeron Corp
19/03/202413:07Business WireGeron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsNASDAQ:GERNGeron Corp
14/03/202419:54Business WireGeron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDSNASDAQ:GERNGeron Corp
28/02/202412:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GERNGeron Corp
28/02/202412:05Business WireGeron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:GERNGeron Corp
22/02/202421:30Business WireGeron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:GERNGeron Corp
16/02/202421:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GERNGeron Corp
16/02/202421:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GERNGeron Corp
16/02/202421:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GERNGeron Corp
 Showing the most relevant articles for your search:NASDAQ:GERN

Your Recent History

LSE
LLOY
Lloyds Banking
LSE
PANR
Pantheon Resources
LSE
GOLD
LSE
EEE
Empire Metals
LSE
GKP
Gulf Keystone Petroleum
LSE
VAST
Vast Resources
LSE
ENET
Ethernity Networks
LSE
NEXN
Nexxen
LSE
QBT
Quantum Blockchain Techn...
LSE
BIRD
Blackbird
LSE
ARCM
Arc Minerals
LSE
AFC
Afc Energy
LSE
TW.
Taylor Wimpey
LSE
SRSP
Sirius Petroleum
LSE
PHNX
Phoenix
LSE
NSCI
Netscientific
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved